Inhibrx Biosciences (INBX) holders disclose 1.49M-share, 9.99% position

Rhea-AI Filing Summary

Perceptive Advisors LLC, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. report beneficial ownership of 1,489,443 shares of Inhibrx Biosciences, Inc. common stock, representing 9.99% of the class. This percentage is based on 14,717,660 shares outstanding as of August 7, 2026, plus shares issuable under certain warrants.

The Master Fund directly holds 1,297,763 common shares and 732,157 pre-funded warrants, each immediately exercisable at $0.0001 per share. Because of a 9.99% Beneficial Ownership Limitation, the reporting group currently may exercise warrants for only 191,680 shares, and assumes the remaining warrants are not exercisable for ownership-calculation purposes. Perceptive Advisors, as investment manager, and Mr. Edelman, as managing member, may be deemed to share voting and dispositive power over the same 1,489,443 shares.

Key Figures

Beneficial ownership: 1,489,443 shares Ownership percentage: 9.99% Shares outstanding: 14,717,660 shares +5 more

8 metrics

Beneficial ownership 1,489,443 shares Shares of Inhibrx Biosciences common stock reported as beneficially owned by the reporting persons

Ownership percentage 9.99% Percent of Inhibrx Biosciences common stock class reported as beneficially owned

Shares outstanding 14,717,660 shares Inhibrx Biosciences common shares outstanding as of August 7, 2026

Common shares held by Master Fund 1,297,763 shares Inhibrx Biosciences common stock directly held by Perceptive Life Sciences Master Fund, Ltd.

Pre-Funded Warrants held 732,157 warrants Pre-Funded Warrants held by the Master Fund, each exercisable into one common share

Warrant exercise price $0.0001 per share Exercise price of the Pre-Funded Warrants for Inhibrx common stock

Currently exercisable warrant shares 191,680 shares Maximum number of shares currently exercisable under the Beneficial Ownership Limitation

Beneficial Ownership Limitation 9.99% Cap on beneficial ownership after warrant exercise as specified in the warrant terms

Key Terms

Beneficial Ownership Limitation, pre-funded warrants, beneficially own, dispositive power, +1 more

5 terms

Beneficial Ownership Limitation regulatory

"The terms of the Pre-Funded Warrants provide that the Pre-Funded Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own... more than 9.99%... (the "Beneficial Ownership Limitation")."

A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.

pre-funded warrants financial

"The Master Fund directly holds 1,297,763 shares of Common Stock and 732,157 pre-funded warrants (the "Pre-Funded Warrants") immediately exercisable..."

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

beneficially own regulatory

"The terms of the Pre-Funded Warrants provide that the Pre-Funded Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own..."

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

dispositive power financial

"Shared Dispositive Power 1,489,443.00... Shared power to dispose or to direct the disposition of: Perceptive Advisors: 1,489,443..."

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Section 13(d) of the Securities Exchange Act of 1934 regulatory

"beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended..."

Section 13(d) of the Securities Exchange Act of 1934 is a U.S. rule that requires anyone who buys more than 5% of a public company’s shares to publicly disclose who they are, how many shares they own, and their intentions toward the company. For investors, this is like a neighborhood alert when someone acquires a large stake in a building: it reveals potential changes in control or strategy that could affect the stock’s price, governance, or future direction.

FAQ

What stake do Perceptive Advisors and affiliates report in INBX?

Perceptive Advisors, Joseph Edelman and Perceptive Life Sciences Master Fund report beneficial ownership of 1,489,443 INBX shares, representing 9.99% of Inhibrx Biosciences’ outstanding common stock, based on 14,717,660 shares outstanding as of August 7, 2026.

How many INBX shares and warrants does the Perceptive Master Fund hold?

Perceptive Life Sciences Master Fund directly holds 1,297,763 INBX common shares and 732,157 pre-funded warrants. Each warrant is immediately exercisable for one common share at an exercise price of $0.0001 per share, subject to an ownership cap.

What is the Beneficial Ownership Limitation described for INBX in this filing?

The Pre-Funded Warrants include a 9.99% Beneficial Ownership Limitation, meaning they cannot be exercised if such exercise would cause the reporting persons to beneficially own more than 9.99% of Inhibrx’s outstanding common stock.

How many INBX warrant shares are currently exercisable by the reporting holders?

Due to the Beneficial Ownership Limitation, the reporting holders state they may currently exercise Pre-Funded Warrants for 191,680 INBX shares. They assume the remaining warrants are not exercisable when calculating beneficial ownership.

On what share count is the 9.99% INBX ownership calculation based?

The reported 9.99% ownership is based on 14,717,660 INBX common shares outstanding as of August 7, 2026, as disclosed in Inhibrx Biosciences’ Quarterly Report on Form 10-Q, plus the warrant shares considered exercisable.

Which entities share voting and dispositive power over the reported INBX shares?

Perceptive Advisors, Joseph Edelman and the Master Fund report shared voting and dispositive power over 1,489,443 INBX shares, with no sole voting or dispositive power reported for any of the three reporting persons.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 05:20 PM Accepted by SEC EDGAR 08/14/2026 - 05:19 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

INHIBRX BIOSCIENCES, INC.

(Name of Issuer)

Common Stock, par value $0.0001

(Title of Class of Securities)

45720N103

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 45720N103

1

Names of Reporting Persons

Perceptive Advisors LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,489,443.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,489,443.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,489,443.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP Number(s): 45720N103

1

Names of Reporting Persons

Joseph Edelman

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,489,443.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,489,443.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,489,443.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP Number(s): 45720N103

1

Names of Reporting Persons

Perceptive Life Sciences Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,489,443.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,489,443.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,489,443.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: INHIBRX BIOSCIENCES, INC.
(b)	Address of issuer's principal executive offices: 11025 N. Torrey Pines Road, Suite 140, La Jolla, California, 92037
Item 2.
(a)	Name of person filing: The names of the persons filing this report (collectively, the "Reporting Persons") with respect to shares of Common Stock, par value $0.0001 (the "Common Stock") of INHIBRX BIOSCIENCES, INC. (the "Issuer") are: (i) Perceptive Advisors LLC ("Perceptive Advisors") (ii) Joseph Edelman ("Mr. Edelman") (iii) Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")
(b)	Address or principal business office or, if none, residence: The address of the principal business office of each of the Reporting Persons is: 51 Astor Place, 10th Floor, New York, NY 10003
(c)	Citizenship: Perceptive Advisors is a Delaware limited liability company. Mr. Edelman is a United States citizen. The Master Fund is a Cayman Islands corporation.
(d)	Title of class of securities: Common Stock, par value $0.0001
(e)	CUSIP No.: 45720N103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 14,717,660 shares of Common Stock outstanding as of August 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2026, and assume the exercise of pre-funded warrants held by the Reporting Persons for 191,680 shares of Common Stock. Neither Perceptive Advisors nor Mr. Edelman directly holds any shares of Common Stock or pre-funded warrants. The Master Fund directly holds 1,297,763 shares of Common Stock and 732,157 pre-funded warrants (the "Pre-Funded Warrants") immediately exercisable for shares of Common Stock at an exercise price of $0.0001 per share, subject to the Beneficial Ownership Limitation (as defined below). The terms of the Pre-Funded Warrants provide that the Pre-Funded Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 9.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the "Beneficial Ownership Limitation"). As of the date hereof, the Beneficial Ownership Limitation permits the Reporting Persons to exercise Pre-Funded Warrants for an aggregate of not more than 191,680 shares of Common Stock. In providing the beneficial ownership information set forth herein, the Reporting Persons have assumed that the remaining Pre-Funded Warrants held by the Reporting Persons are not exercisable due to the Beneficial Ownership Limitation. Perceptive Advisors serves as the investment manager of the Master Fund and may be deemed to beneficially own such shares. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own such shares.
(b)	Percent of class: Perceptive Advisors: 9.99% Mr. Edelman: 9.99% Master Fund: 9.99%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0
	(ii) Shared power to vote or to direct the vote: Perceptive Advisors: 1,489,443 Mr. Edelman: 1,489,443 Master Fund: 1,489,443
	(iii) Sole power to dispose or to direct the disposition of: Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0
	(iv) Shared power to dispose or to direct the disposition of: Perceptive Advisors: 1,489,443 Mr. Edelman: 1,489,443 Master Fund: 1,489,443
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Perceptive Advisors LLC

Signature:	/s/ Joseph Edelman
Name/Title:	Joseph Edelman, Managing Member
Date:	08/14/2026

Joseph Edelman

Signature:	/s/ Joseph Edelman
Name/Title:	Joseph Edelman
Date:	08/14/2026

Perceptive Life Sciences Master Fund, Ltd.

Signature:	/s/ Joseph Edelman
Name/Title:	Joseph Edelman, Managing Member
Date:	08/14/2026